$EQ
Equillium, Inc.

2019 Q3 Form 10-Q Financial Statement

#000156459019042933 Filed on November 12, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2018 Q3 2018 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.140M $1.000M
YoY Change 114.0% 3233.33%
% of Gross Profit
Research & Development $4.182M $1.220M $540.0K
YoY Change 242.79% 2342.49%
% of Gross Profit
Depreciation & Amortization $10.00K $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $6.324M $2.226M $1.125M
YoY Change 184.1% -2759.15% -222.1%
Operating Profit -$6.324M -$2.226M -$1.125M
YoY Change 184.11% 2559.01%
Interest Expense $320.0K -$2.690M
YoY Change -111.9% 4383.33%
% of Operating Profit
Other Income/Expense, Net $310.0K -$2.691M -$640.0K
YoY Change -111.52% 4594.39%
Pretax Income -$6.010M -$4.920M
YoY Change 22.15% 3414.29%
Income Tax
% Of Pretax Income
Net Earnings -$6.014M -$4.917M -$1.765M
YoY Change 22.31% 3386.62% 86.32%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$345.8K -$444.0K
COMMON SHARES
Basic Shares Outstanding 17.38M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2018 Q3 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $62.20M $5.000M $6.600M
YoY Change 1144.0%
Cash & Equivalents $27.66M $4.983M $6.626M
Short-Term Investments $34.60M
Other Short-Term Assets $700.0K $100.0K $100.0K
YoY Change 600.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $62.90M $5.060M $6.700M
YoY Change 1143.01%
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K $31.89K $0.00
YoY Change 213.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $1.300M
YoY Change -100.0%
Total Long-Term Assets $100.0K $1.361M $0.00
YoY Change -92.65%
TOTAL ASSETS
Total Short-Term Assets $62.90M $5.060M $6.700M
Total Long-Term Assets $100.0K $1.361M $0.00
Total Assets $63.00M $6.422M $6.700M
YoY Change 881.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.700M $1.230M $300.0K
YoY Change 119.47%
Accrued Expenses $1.600M $1.449M $600.0K
YoY Change 10.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.300M $2.680M $900.0K
YoY Change 60.46%
LONG-TERM LIABILITIES
Long-Term Debt $9.616M $11.60M $10.50M
YoY Change -17.1%
Other Long-Term Liabilities $146.0K $148.7K $900.0K
YoY Change -1.83%
Total Long-Term Liabilities $9.762M $148.7K $11.40M
YoY Change 6463.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.300M $2.680M $900.0K
Total Long-Term Liabilities $9.762M $148.7K $11.40M
Total Liabilities $14.04M $16.80M $12.30M
YoY Change -16.45%
SHAREHOLDERS EQUITY
Retained Earnings -$33.55M
YoY Change
Common Stock $82.42M $141.7K
YoY Change 58071.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $48.96M -$10.38M -$5.593M
YoY Change
Total Liabilities & Shareholders Equity $63.00M $6.400M $6.700M
YoY Change 884.3%

Cashflow Statement

Concept 2019 Q3 2018 Q3 2018 Q2
OPERATING ACTIVITIES
Net Income -$6.014M -$4.917M -$1.765M
YoY Change 22.31% 3386.62% 86.32%
Depreciation, Depletion And Amortization $10.00K $0.00 $0.00
YoY Change
Cash From Operating Activities -$4.700M -$1.640M -$2.060M
YoY Change 186.59% 1722.22% 1044.44%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$10.00K -$20.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$230.0K
YoY Change
Cash From Investing Activities -$230.0K -$10.00K -$20.00K
YoY Change 2200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.940M 0.000 1.600M
YoY Change 60.0%
NET CHANGE
Cash From Operating Activities -4.700M -1.640M -2.060M
Cash From Investing Activities -230.0K -10.00K -20.00K
Cash From Financing Activities 9.940M 0.000 1.600M
Net Change In Cash 5.010M -1.650M -480.0K
YoY Change -403.64% 1733.33% -158.54%
FREE CASH FLOW
Cash From Operating Activities -$4.700M -$1.640M -$2.060M
Capital Expenditures $0.00 -$10.00K -$20.00K
Free Cash Flow -$4.700M -$1.630M -$2.040M
YoY Change 188.34% 1711.11% 1033.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17376236
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17376236
CY2018Q3 eq Change In Fair Value Adjustment Of Anti Dilution Right
ChangeInFairValueAdjustmentOfAntiDilutionRight
1497000
eq Change In Fair Value Adjustment Of Anti Dilution Right
ChangeInFairValueAdjustmentOfAntiDilutionRight
1599000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4182000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6324000
CY2019Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
146000
CY2019Q3 us-gaap Liabilities
Liabilities
14036000
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
82423000
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
80000
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33545000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
48959000
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62995000
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
7000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-7000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
75000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6021000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4917000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17958000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8259000
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.04
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.76
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17376236
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11078840
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17376236
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10835483
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-2252000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1577000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-3829000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-1765000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-5593000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
131000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
-10379000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
19000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
446000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
44000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5950000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
59494000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
19000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
581000
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
38000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-6069000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
54063000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
18000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
633000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
266000
us-gaap Profit Loss
ProfitLoss
-18033000
us-gaap Profit Loss
ProfitLoss
-8259000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
17000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4000
us-gaap Share Based Compensation
ShareBasedCompensation
1660000
us-gaap Share Based Compensation
ShareBasedCompensation
131000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-2329000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
327000
us-gaap Other Noncash Expense
OtherNoncashExpense
19000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-495000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
32000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1559000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
353000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
694000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
175000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13916000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3700000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
56000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
36095000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
39315000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3164000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
9941000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1599000
eq Proceeds From Exercise Of Stock Options Including Early Exercise
ProceedsFromExerciseOfStockOptionsIncludingEarlyExercise
199000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
195000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9941000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1603000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-40000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-851000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2122000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28508000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7104000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27657000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4982000
eq Fair Value Of Common Stock Warrants In Connection With Issuance Of Notes Payable
FairValueOfCommonStockWarrantsInConnectionWithIssuanceOfNotesPayable
266000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
58000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s condensed consolidated financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the condensed consolidated financial statements and accompanying notes. Significant estimates in the Company&#8217;s condensed consolidated financial statements relate to clinical trial accruals and the valuation of equity awards. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company&#8217;s historical experience, knowledge of current events, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. </p>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2017-03-16
CY2019Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
62200000
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1283911
CY2019Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
34581000
CY2018Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
37405000
CY2019Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
34507000
CY2019Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
37400000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities
0
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
969000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
560000
CY2019Q3 eq Accrued Clinical Studies
AccruedClinicalStudies
425000
CY2018Q4 eq Accrued Clinical Studies
AccruedClinicalStudies
245000
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
201000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
96000
CY2019Q3 eq Accrued Preclinical Studies
AccruedPreclinicalStudies
4000
CY2018Q4 eq Accrued Preclinical Studies
AccruedPreclinicalStudies
8000
us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2024-06-01
CY2019Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
300000
CY2019Q3 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal In Year Three
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalInYearThree
1667000
CY2019Q3 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal In Year Four
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalInYearFour
3333000
CY2019Q3 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal In Year Five
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalInYearFive
3333000
CY2019Q3 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal After Year Five
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalAfterYearFive
2117000
CY2019Q3 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFee
10450000
CY2019Q3 eq Unaccreted Liability For Final Payment Fee
UnaccretedLiabilityForFinalPaymentFee
450000
CY2019Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
384000
CY2019Q3 us-gaap Long Term Debt
LongTermDebt
9616000
CY2019Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9616000
CY2017Q2 us-gaap Proceeds From Sale Of Available For Sale Securities Equity
ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
15000000
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3249878
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2126877
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
633000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
131000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1660000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
131000

Files In Submission

Name View Source Status
0001564590-19-042933-index-headers.html Edgar Link pending
0001564590-19-042933-index.html Edgar Link pending
0001564590-19-042933.txt Edgar Link pending
0001564590-19-042933-xbrl.zip Edgar Link pending
eq-10q_20190930.htm Edgar Link pending
eq-20190930.xml Edgar Link completed
eq-20190930.xsd Edgar Link pending
eq-20190930_cal.xml Edgar Link unprocessable
eq-20190930_def.xml Edgar Link unprocessable
eq-20190930_lab.xml Edgar Link unprocessable
eq-20190930_pre.xml Edgar Link unprocessable
eq-ex101_44.htm Edgar Link pending
eq-ex311_7.htm Edgar Link pending
eq-ex312_8.htm Edgar Link pending
eq-ex321_6.htm Edgar Link pending
eq-ex42_45.htm Edgar Link pending
eq-ex43_43.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending